


PHARMACEUTICAL 2017

## FIVE PRIME THERAPEUTICS INC. Rank 47 of 313







PHARMACEUTICAL 2017



FIVE PRIME THERAPEUTICS INC. Rank 47 of 313

The relative strengths and weaknesses of FIVE PRIME THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of FIVE PRIME THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 209% points. The greatest weakness of FIVE PRIME THERAPEUTICS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 75%, being 492% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	440,125
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	38,741
Liabilities, Non-Current	0
Other Assets	1,949
Other Compr. Net Income	35
Other Expenses	-31,048
Other Liabilities	0
Other Net Income	33,158
Property and Equipment	6,207
Research and Development	94,072
Revenues	0
Selling, General and Administrative Expense	35,831

Output Variable	Value in 1000 USD
Assets	448,281
Liabilities	38,741
Expenses	98,855
Stockholders Equity	409,540
Net Income	-65,697
Comprehensive Net Income	-65,680
Economic Capital Ratio	75%

